Seeking Alpha

Merck, Glaxo to test combo treatment in renal cell carcinoma

  • Merck (MRK) is set to collaborate with GlaxoSmithKline (GSK) to test a MK-3475 (that's the PD-1 inhibitor)/ pazopanib combo in advanced renal cell carcinoma.
  • MRK senior VP Iain Dukes says "collaborations like this are central to MRK's strategy to evaluate the potential of MK-3475 for the treatment of cancer."
  • The companies have initiated a Phase 1/2 trial in treatment naïve patients. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: